Condition Information
Degenerative myopia is the seventh leading cause of legal blindness, occurring in about 2% of the U.S. population. It is most often seen in people of Chinese, Japanese, Middle Eastern and Jewish descent. This condition can start at birth, but most often starts during the pre-teen years. It is believed to be hereditary.
Degenerative myopia is more severe than other forms of myopia and is associated with retina changes, potentially causing severe vision loss. It progresses rapidly, and visual outcome depends largely on the extent of fundus and lenticular changes. The diagnosis of degenerative myopia is accompanied by characteristic chorioretinal degenerations. Pathologic myopes, particularly those with higher refractive errors, are at risk for retinal detachment and macular changes.
Patients with degenerative myopia typically complain of decreased vision, headaches, and sensitivity to light. If retinal degeneration or detachment is present, patients may also report light flashes and floaters, which are associated with retina changes. Those with degenerative myopia have an increased incidence of cataract formation (nuclear cataracts are most typical).
Some of the most typical features of degenerative myopia are:
- Vitreous liquefaction and posterior vitreous detachment
- Peripapillary atrophy appearing as temporal choroidal or scleral crescents or rings around the optic disc
- Lattice degeneration in the peripheral retina
- Tilting or malinsertion of the optic disc, usually associated with myopic conus
- Thinning of the retinal pigment epithelium with resulting atrophic appearance of the fundus
- Ectasia of the sclera posteriorly (posterior staphyloma)
- Breaks in Bruch’s membrane and choriocapillaris, resulting in lines across the fundus called “lacquer cracks”
- Fuch’s spot in the macular area
Myopic degeneration is similar to age-related macular degeneration AMD) in that it causes loss of central vision due to degeneration of the photoreceptor cells. This is caused by separation of the retina as a result of abnormal elongation of the eyeball. This usually happens because the back of the eye is larger than normal when the eye is very nearsighted. Marked thinning and stretching may lead to break down of the macula, surrounding retina and it’s underlying tissue. This will cause a varying amount of blurred vision.
Even after the eyeball has fully grown (by adulthood), weakness in the sclera (the white outer shell) can lead to development of a posterior staphyloma. This is a distention of the sclera at the back of the globe where the optic disc and macula are located. Breaks in Bruch’s membrane and atrophy of the choroid layer of the retina (where the blood vessels are) can create lesions known as lacquer cracks. Blood vessels may protrude through the cracks and leak into the subretinal space beneath the photoreceptor cells. Known as “choroidal neovascularization,” this hemorrhaging can lead to scarring, retinal separation, and profound sight loss in the central field. If this occurs, immediate treatment is needed, which may be in the form of photodynamic therapy, antiangiogenic drug treatment or both.
Treatment Information
Four treatments are showing promise. One is scleral buckling, which can be read about in the article, Degenerative Myopia: a Review of its Nature and its Treatment.
A second treatment is early systemic treatment with 7-methylxanthine, which has been shown to normalize the abnormal growth pattern of myopic eyes in children aged 8-13. In the abstract, “Effect of 7-methylxanthine on eye growth in myopic children” (Ophthalmic and Physiological Optics, Vol. 26, Suppl. 1, August 2006), researchers Klaus Trier and Soren Munk Ribel-Madsen reported that “axial growth in the 7-methylxanthine group was reduced by 22% in the low axial growth stratification layer and by 8% in the high axial growth layer compared with placebo. The myopia progression in the two layers was reduced by 21% and 12%.” This study was based upon the success of earlier research, in which 7-methylxanthine increased the content of collagen and proteoglycans (connective tissue components of the sclera) as well as the diameter of collagen fibrils in rabbits. Excessive eye elongation is related to abnormal organization and reduced content of these components.
Contact lenses are being looked at as a possible means of slowing axial lengthening in children. Soft multifocal contact lenses have been shown to reduce myopia progression in children by as much as 50% (Walline, Jeffrey J. et al. “Multifocal Contact Lens Myopia Control.” Optometry and Vision Science 90.11 (2013):1207-1214.) Clinical trials are underway.
Finally, off-label use of atropine eye drops in a trial at Singapore National Eye Centre appeared to reduce the progression of myopia in children. Low-dose atropine trials have been scheduled for children in Japan and the U.K. In Singapore, nearly 1,000 children have been in enrolled in 0.01% treatment programs for further research. The updated trial results will be published in Ophthalmology in February 2016. (Source: Tan D, et al “Five-year clinical trial on atropine for the treatment of myopia2: myopia control with atropine 0.01% eyedrops” AAO 2015.)